I-MAB - AMERICAN DEPOSITARY SHARES
I-MAB - AMERICAN DEPOSITARY SHARES
Certificado de depósito · US44975P1030 · IMAB · A2PVC6 (XNAS)
Resumen
2,49 USD
-0,40 % -0,010 USD
NASDAQ (XNAS) · Precios actuales y gráficos en MoneyPeak
13.06.2025 23:46

Cotizaciones actuales de I-MAB - AMERICAN DEPOSITARY SHARES

BolsaTickerMonedaÚltima operaciónPrecioVariación diaria
XNAS: NASDAQ
NASDAQ
IMAB
USD
13.06.2025 23:46
2,49 USD
2,64 USD
-5,50 %

Rendimiento

Día Semana Mes 3 meses 6 meses 1 año 5 años
0,00 % -1,19 % 179,34 % 196,08 % 156,70 % 35,33 % -89,63 %

Perfil de la empresa para I-MAB - AMERICAN DEPOSITARY SHARES Certificado de depósito

I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinical trials to treat pediatric growth hormone deficiency; TJ107, a recombinant human IL-7, which is in Phase 2 for cancer treatment-related lymphopenia and cancer immunotherapy; and Lemzoparlimab, a CD47 monoclonal antibody that has completed Phase 2 clinical trial. Its product candidates also includes Enoblituzumab, a humanized B7-H3 antibody that is in Phase 2 to treat head and neck cancer, and other oncology diseases; Efineptakin, a long-acting recombinant human IL-7, which is in Phase 2 clinical trials to treat lymphopenia and cancer immunotherapy; TJ210, a monoclonal antibody against human C5aR1 that is in Phase 1 for the treatment of cancers and autoimmune; Plonmarlimab, a GM-CSF monoclonal antibody for inflammation and CRS-related therapies; Uliledlimab, a CD73 antibody, which is in Phase 2 clinical trials for treating solid tumors and oncology; TJ-L14B, a PD-L1-based tumor-dependent T-cell engager for solid cancers; and TJ-CD4B, a tumor-dependent T cell engager for gastric and other cancers, as well as TJ-L1IF, a PD-L1/IFN-a antibody-cytokine fusion protein for solid tumors and TJ-C64B, a tumor-dependent T-cell engager for ovarian and other cancers. I-Mab has strategic collaboration agreement with AbbVie Ireland Unlimited Company; Sinopharm Group Co. Ltd.; PT Kalbe Genexine Biologics; and Roche Diagnostics. The company was founded in 2014 and is headquartered in Shanghai, the People's Republic of China.

Fondos invertidos

Los siguientes fondos han invertido en: I-MAB - AMERICAN DEPOSITARY SHARES invertido:

Fondo
iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)
Vol. en millones
75,32
Porcentaje (%)
0,18 %
Fondo
iShares MSCI China UCITS ETF USD (Dist)
Vol. en millones
2,68
Porcentaje (%)
0,08 %
Fondo
iShares MSCI EM ESG Enhanced UCITS ETF USD (Dist)
Vol. en millones
110,45
Porcentaje (%)
0,04 %
Fondo
iShares MSCI EM ESG Enhanced UCITS ETF USD (Acc)
Vol. en millones
465,11
Porcentaje (%)
0,04 %
Fondo
iShares MSCI AC Far East ex-Japan UCITS ETF USD (Acc)
Vol. en millones
7,88
Porcentaje (%)
0,04 %

Datos de la empresa

Nombre I-MAB - AMERICAN DEPOSITARY SHARES
Empresa I-Mab
Símbolo IMAB
Sitio web https://www.i-mabbiopharma.com
Mercado principal XNAS NASDAQ
WKN A2PVC6
ISIN US44975P1030
Tipo de valor Certificado de depósito
Sector Healthcare
Industria Biotechnology
CEO Dr. Xi-Yong Fu M.B.A., Ph.D.
Capitalización de mercado 69 Mio
País China
Moneda USD
Empleados 0,0 T
Dirección New Bund Center, 200124 Shanghai
Fecha de OPV 2020-01-17

Símbolos de cotización

Nombre Símbolo
Frankfurt 0VY.F
NASDAQ IMAB

Otras acciones

Los inversores que tienen I-MAB - AMERICAN DEPOSITARY SHARES también tienen las siguientes acciones en su cartera:
BECTON,DICKINS. 2022 FLR
BECTON,DICKINS. 2022 FLR Bono
EUROPEAN BANK FOR RECONSTRUCTION & DEVELOPMENT 75.00% NTS 01/12/21
EUROPEAN BANK FOR RECONSTRUCTION & DEVELOPMENT 75.00% NTS 01/12/21 Bono
La plataforma financiera MoneyPeak rastrea y analiza inversiones y carteras. Desde depósitos de valores hasta compras de criptomonedas.
Útil, simple y gratuito. Acciones, ETF, ETC, ETN, índices, fondos, bonos, certificados, divisas, opciones, derechos de suscripción.
Aviso legal Protección de datos Blog Comunidad Comentarios Changelog
Im App Store herunterladen Bei Google Play herunterladen
Todos los derechos reservados © LCP GmbH 2025